Featured content in this Issue:
- Incannex Shares Topline Results from Phase 2a Study of Psilocybin for Generalised Anxiety Disorder
- An Uptick in Psilocybin-Related Poison Centre Calls
- Compass Pushes Back First Phase 3 Readout to Q4
- GH Research Preparing to Conduct Phase 1 Study of Proprietary Device in Europe if FDA Hold Not Resolved
- Further Reading & Other Stories
Companies and candidates mentioned in this Bulletin: Incannex Healthcare, PSX-001, MindMed, MM-120, Cybin, CYB004, Compass Pathways, GH Research, GH001, Enveric Biosciences, atai Life Sciences, aNUma.
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
